FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
127 letters match. Newest first.
-
DrugsRonanRx, Inc. dba RonanRx
FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.
Low -
DrugsZhejiang Gaorong Cosmetic Co., Ltd.
FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.
High risk -
DrugsJiangmen Shuizirun Sanitary Articles Co., Ltd.
FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.
High risk -
DrugsBabikian Healthcare Products CJSC
FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.
High risk -
DrugsBentley Laboratories LLC
Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.
High risk -
DrugsStream2Sea, LLC
FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.
Medium -
DrugsHappy Farm Botanicals, Inc.
Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.
High risk -
DrugsThomas Brunner Hygiene GmbH
Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.
High risk -
DrugsAHC Products, Inc.
AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.
High risk -
DrugsAmie Health, Inc. dba Amie
FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.
Medium -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsMacau-Union Pharmaceutical Limited
Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.
High risk -
DrugsGSC Products, LLC
FDA told GSC Products its Sinus Plumber headache nasal spray is an unapproved new drug sold online without FDA approval.
High risk -
DrugsPro Numb Tattoo Numbing Spray, LLC
FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.
High risk -
DrugsApothecary Pharma, LLC
FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.
High risk -
DrugsPremium Health Management Inc. dba Premium Health
FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.
Low -
DrugsKare Solutions, LLC dba Zappy
FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.
Low -
DrugsPeaks Curative, LLC dba Peaks
FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.
Low -
DrugsMaxLife Technologies Inc. dba Maxlife
FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.
Medium -
DrugsBetter Health Labs, Inc. dba Measured
FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.
Medium -
DrugsFitRX, LLC dba FitRx
FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.
Medium -
DrugsSignature Formulations, LLC
FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.
High risk -
DrugsCohance Lifesciences Limited
Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.
High risk -
DrugsFulijaya Manufacturing SDN. BHD.
Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.
High risk -
DrugsGuangdong Renhe Guozhuang Biotechnology Co., Ltd.
FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.
High risk -
DrugsCDL Services, Inc. DBA Technichem
FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.
High risk -
DrugsSinsin Pharmaceutical Co., Ltd.
FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.
High risk -
DrugsKath Khemicals LLC
FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.
High risk -
DrugsGuangxi Yulin Pharmaceutical Group Co. Ltd.
FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.
High risk -
DrugsHealth and Natural Beauty USA Corp.
FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.
High risk -
Drugscheaptrustedpharmacy.com
cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.
High risk -
DrugsFWD Care, Inc. dba FWD
FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.
Medium -
DrugsDermacare LLC dba BlueChew
FDA warned BlueChew over website claims that its compounded sildenafil and tadalafil are the same as Viagra and Cialis.
High risk -
DrugsiVisitDoc, Inc. dba iVisitDoc
FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.
Medium -
DrugsHello Cake, Inc. dba Hello Cake
FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.
Medium -
DrugsBody Good Studio
FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.
High risk -
DrugsMatthew Stern, CEO MyStart Health LLC.
FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.
Low -
DrugsCurex
FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.
High risk -
DrugsHikal Limited
FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.
High risk -
DrugsKalani AB dba Kalani Sunwear
FDA warns Kalani AB that its Sun Mousse SPF 50 sunscreen is an unapproved, misbranded drug for US sale.
High risk -
DrugsGlenmark Pharmaceuticals Limited
FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.
High risk -
DrugsScope Health Inc
FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.
High risk -
DrugsRevitalize Energy, Inc.
FDA warned Revitalize Energy that its Revitalize Energizing Eye Drops are an unapproved new drug and misbranded.
High risk -
DrugsThea Pharma, Inc.
FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.
High risk -
DrugsEyeTech One, LLC
FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.
Medium -
DrugsXtreme Tools International, Inc.
FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.
High risk -
DrugsDynamic Blending Specialists, Inc.
FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.
High risk -
DrugsZhejiang Huahai Pharmaceutical Co., Ltd.
FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.
High risk -
DrugsHorizon Tool Inc.
FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.
High risk -
DrugsZhejiang Easyclean Daily Chemical Co., Ltd
FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.
High risk